248 related articles for article (PubMed ID: 12839095)
1. The cellular and clinical parameters of anabolic therapy for osteoporosis.
Rosen CJ
Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy-associated plasma protein-A modulates the anabolic effects of parathyroid hormone in mouse bone.
Clifton KB; Conover CA
Bone; 2015 Dec; 81():413-416. PubMed ID: 26297833
[TBL] [Abstract][Full Text] [Related]
3. New anabolic therapies in osteoporosis.
Rubin MR; Bilezikian JP
Curr Opin Rheumatol; 2002 Jul; 14(4):433-40. PubMed ID: 12118181
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
5. Anabolic agents for treating postmenopausal osteoporosis.
Meunier PJ
Joint Bone Spine; 2001 Dec; 68(6):576-81. PubMed ID: 11809001
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
[TBL] [Abstract][Full Text] [Related]
7. New mechanisms and targets in the treatment of bone fragility.
Martin TJ; Seeman E
Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.
Whitfield JF; Morley P; Willick GE
Treat Endocrinol; 2002; 1(3):175-90. PubMed ID: 15799210
[TBL] [Abstract][Full Text] [Related]
9. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
[TBL] [Abstract][Full Text] [Related]
10. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
Adami S
Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
[TBL] [Abstract][Full Text] [Related]
11. New anabolic therapies in osteoporosis.
Rubin MR; Bilezikian JP
Endocrinol Metab Clin North Am; 2003 Mar; 32(1):285-307. PubMed ID: 12699304
[TBL] [Abstract][Full Text] [Related]
12. Reconstructing the skeleton with intermittent parathyroid hormone.
Seeman E; Delmas PD
Trends Endocrinol Metab; 2001 Sep; 12(7):281-3. PubMed ID: 11504661
[TBL] [Abstract][Full Text] [Related]
13. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
Delmas PD; Vergnaud P; Arlot ME; Pastoureau P; Meunier PJ; Nilssen MH
Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
[TBL] [Abstract][Full Text] [Related]
14. Emerging anabolic treatments for osteoporosis.
Rosen CJ; Rackoff PJ
Rheum Dis Clin North Am; 2001 Feb; 27(1):215-33, viii. PubMed ID: 11285997
[TBL] [Abstract][Full Text] [Related]
15. Miscellaneous and experimental agents.
Reginster JY
Am J Med Sci; 1997 Jan; 313(1):33-40. PubMed ID: 9001164
[TBL] [Abstract][Full Text] [Related]
16. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
17. What's new with PTH in osteoporosis: where are we and where are we headed?
Rosen CJ
Trends Endocrinol Metab; 2004 Jul; 15(5):229-33. PubMed ID: 15223053
[TBL] [Abstract][Full Text] [Related]
18. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
19. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
Compston JE
Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
[TBL] [Abstract][Full Text] [Related]
20. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
